8 completed, 1 active not recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Qlaris Bio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Active not recruiting | Qlaris Bio, Inc. | 14 | 2026-02-20 | 2026-09-14 |
| Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral | Phase 2 | Completed | Qlaris Bio, Inc. | 37 | 2025-08-13 | 2026-04-03 |
| Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075% - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Qlaris Bio, Inc. | 36 | 2024-04-21 | 2025-01-20 |
| Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%) - Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes | Phase 2 | Completed | Qlaris Bio, Inc. | 63 | 2024-03-05 | 2025-01-20 |
| Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) QLS-101 ophthalmic solution, 2.0 % - Sturge-Weber Syndrome, Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 2 | 2022-11-23 | 2025-01-20 |
| A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2% - Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 3 | 2021-10-19 | 2025-01-20 |
| A Study to Evaluate Safety and Tolerability of QLS-101 in NTG QLS-101, Timolol maleate PF 0.5% ophthalmic solution - Normal Tension Glaucoma (NTG) | Phase 2 | Completed | Qlaris Bio, Inc. | 30 | 2021-09-15 | 2025-01-20 |
| Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). QLS-101, Timolol Maleate - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Qlaris Bio, Inc. | 84 | 2021-03-31 | 2025-01-17 |
Glaucoma (8) · Ocular Hypertension (6) · Glaucoma, Open-Angle (5) · Low Tension Glaucoma (3) · Sturge-Weber Syndrome (2) · Diabetic Retinopathy (1) · Hydrophthalmos (1)
Timolol (3) · Ophthalmic Solutions (2) · Latanoprost (1)
United States (8) · South Korea (1)
Lisa Brandano (3) · B. Wirostko, M.D. (2) · Barbara M Wirostko, MD (2) · Sharon Freedman, M.D. (1)